IL33 and systemic lupus erythematosus: Anti–IL-33 and/or aST2L antibodies are currently under clinical development (72); in a preliminary report, administration of anti–IL-33 antibody in MRL/lpr lupus–prone mice reduced anti-dsDNA and IC levels, kidney inflammation, and proteinuria (31).